AstraZeneca Investor Day Presentation Deck
Progression free survival
Probability of PFS
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Number of subjects at risk
Durvalumab + GemCis
Placebo + GemCis
341
344
6-mo PFS:
58.3%
47.2%
258
255
6
189
149
Durvalumab + GemCis (n=341)
Placebo + GemCis (n=344)
Statistical significance cut-off for PFS: p=0.0481
9
100
71
9-mo PFS:
34.8%
24.6%
38
17
12-mo PFS:
16.0%
6.6%
12
15
18
Time from randomization (months)
13 Median duration of follow-up (95% CI) was 9.2 (0.0-24.0) months with durvalumab + GemCis and 6.9 (0.0-20.4) months with placebo + GemCis.
CI, confidence interval; GemCis, gemcitabine and cisplatin; PFS, progression-free survival.
Median PFS
(95% CI), months
7.2 (6.7-7.4)
5.7 (5.6-6.7)
25
7
15
4
21
5
оu
0
Hazard ratio
(95% CI)
0.75
(0.63-0.89)
24
0
27
p-value
0.001
30View entire presentation